KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 96 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $459 | – | 39 | – | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 42 | -62.5% | 0.00% | – |
| Q1 2022 | $2,000 | -88.2% | 112 | -88.8% | 0.00% | -100.0% |
| Q3 2021 | $17,000 | -63.0% | 1,000 | -44.4% | 0.00% | -60.0% |
| Q1 2021 | $46,000 | +206.7% | 1,800 | +44.0% | 0.01% | +66.7% |
| Q3 2019 | $15,000 | +200.0% | 1,250 | +316.7% | 0.01% | +200.0% |
| Q4 2018 | $5,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,579,490 | $20,146,000 | 22.25% |
| Novo Holdings A/S | 2,901,927 | $22,664,000 | 2.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 322,436 | $2,518,000 | 0.96% |
| Vivo Capital, LLC | 300,325 | $2,346,000 | 0.69% |
| VHCP Management II, LLC | 221,651 | $1,635,000 | 0.67% |
| RA Capital Management | 591,070 | $4,616,000 | 0.57% |
| INTERWEST VENTURE MANAGEMENT CO | 329,942 | $2,577,000 | 0.55% |
| Eventide Asset Management | 98,100 | $766,000 | 0.05% |
| BOOTHBAY FUND MANAGEMENT, LLC | 21,665 | $169,000 | 0.03% |
| A.R.T. Advisors, LLC | 11,116 | $86,000 | 0.00% |